secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001193125-26-030518
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance
--------------------------------------------------------------------------------

- Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
- Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.
- Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.
- If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.
- Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312526030518/0001193125-26-030518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312526030518/d72347d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-030518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer